Endocrine Abstracts

Castrate Resistant Prostate Cancer (CRPC) is the inevitable outcome of hormone treatment for advanced disease. Although no longer dependent on high levels of androgens, the androgen receptor (AR) remains active and there is evidence that other nuclear receptors (NRs) can drive CRPC progression and/or therapy resistance. NRs share a repertoire of essential coregulators: proteins possessing the ability to aid or repress NR action and have been proposed as a potential mechanism f...

The stromal compartment changes with cancer, with an emergence in activated fibroblasts. These stromal changes, which occur with cancer initiation and throughout progression, are known to influence the hallmarks of cancer and are becoming increasingly studied for prognostic and therapeutic purposes. Androgen receptor (AR) signalling in stromal cells is important in prostate cancer and these cancer stromal communications, yet the mechanisms underpinning stromal AR contribution ...

Liver X receptors (LXRs) are are ligand-dependent transcription factors, members of the nuclear receptor superfamily of transcription factors. In humans two LXR isoforms exist, LXRα (NR1H3) and LXRβ (NR1H2). LXRα is expressed predominantly in metabolically active tissues, while LXRβ is expressed in the majority of tissues. They have long been known to have critical roles in regulation of lipid metabolism, particu...

Androgens initially drive prostate tumour growth. Although in advanced disease there is no longer dependence on circulating androgens, the androgen receptor (AR) remains a key driver of this lethal stage thus new ways to inhibit its activity are required. MicroRNAs play vital roles in prostate cancer (PCa) development, progression and metastasis. Previous studies have examined microRNAs dysregulated in PCa, and also identified androgen-regulated microRNAs. We approached microR...